- Zacks•2 hours ago
Allergan plc (AGN) will be reporting third-quarter 2016 earnings on Nov 2, before market open. Last quarter, the company delivered a positive earnings surprise of 2.13%.
- American City Business Journals•3 hours ago
Allergan has announced it will acquire Boston-based Motus Therapeutics for $200 million. Motus, a wholly-owned subsidiary of Rhythm Holding Co. which also owns Rhythm Pharmaceuticals, is focused on developing peptide therapeutics for gastrointestinal disease. Allergan (AGN) previously paid $47 million for the option to acquire Motus, funding that also went to support Phase 2b clinical trials.
- American City Business Journals•6 hours ago
Allergan successfully completed its tender offer for all the outstanding shares of Vitae Pharmaceuticals Inc., a clinical-stage biopharmaceutical company based in Fort Washington, Montgomery County. Under the terms of the $639 million deal, Allergan (AGN) paid Vitae stockholders $21 per share. “The completion of the Vitae acquisition will add highly differentiated development compounds and bolsters our innovative medical dermatology pipeline,” said David Nicholson, chief research and development officer at Allergan.
Allergan plc (AGN)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||221.70 x 200|
|Ask||221.80 x 100|
|Day's Range||221.33 - 224.91|
|52wk Range||195.50 - 322.68|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||21.10|
|Avg Vol (3m)||3,301,864|
|Dividend & Yield||N/A (N/A)|